High anxiety. This may best capture the current mood of many in the biotech industry. The following Xconomy Special Report takes a deep dive into the emerging issues posing an existential threat to the health of our industry. It is a worthy read. In times of crisis, effective preparedness is key.
In this Report, veteran biotech journalists Alex Lash and Ben Fidler bring you deep insights, based on conversations with key industry leaders, on what 2019 and beyond hold for biopharma companies. You’ll learn:
• The key indicators that suggest a possible downturn is on the way.
• What biopharma leaders, Jim Greenwood of BIO, Abbie Celniker of Third Rock Ventures, and others, are saying about what these uncertain times mean for the industry.
• Practical tips for young companies and investors on how to brace for rough seas ahead.
Once prepared, learn more on how you can join innovative life science leaders to drive even more breakthroughs in drug development through networking and partnering at BioPharm America™, September 11—12 in Boston.